Cold-cough

Commercial

Portfolio-7447-for-WEB

NCE Pipeline

Discovery-7447-for-WEB

Research

Latest Annual Report

Vernalis-AR2013-CoverApr 01, 2014

2013 Results Download our latest report...        


Archive

Latest Webcast

ceoApril 01, 2014

Our latest webcast is available to view here...


Archive

Share Price

Share price:  44.75p
Change:  -1.25 (-2.72%)
As at:  19 September 2014 18:15:01
Volume:  18,061
LSE ID:  VER

Share price details

Latest News

FDA accepts Tuzistra™ XR (CCP-01) NDA for full review

Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that the U.S. Food and Drug Administration ("FDA") has confirmed that the New Drug Application ("NDA") for TuzistraTM XR ("CCP-01") has been accepted for full review.

Read more...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form